📋 Clinical Overview

Granulocyte Colony-Stimulating Factor (G-CSF) is a recombinant human glycoprotein hormone (rHuG-CSF) that stimulates the proliferation, differentiation, and functional activation of neutrophil progenitor cells and mature neutrophils. The 6mg formulation is a high-dose, long-acting pegylated version (Pegfilgrastim) designed for single-dose administration per chemotherapy cycle. It is a critical supportive care agent in oncology to prevent febrile neutropenia.

💊 Dosage & Administration

Adult: 6mg (0.6ml of 10mg/ml solution) as a single subcutaneous injection per chemotherapy cycle, administered approximately 24 hours after completion of chemotherapy.

Note: For subcutaneous use only. Administer in the abdomen (except 2-inch area around navel), thigh, or back of upper arm. Rotate injection sites. Allow prefilled syringe to reach room temperature for 30 minutes before injection. Do not shake. Inspect for particulate matter or discoloration. Use a 27-gauge needle. Do not administer intravenously.

⚠️ Contraindications

Hypersensitivity to Filgrastim, Pegfilgrastim, E. coli-derived proteins, or any component.
Simultaneous administration with chemotherapy or radiotherapy (must be spaced 24 hrs post-chemo).

🔬 Mechanism of Action

Binds to specific cell surface receptors (G-CSFR) on myeloid progenitor cells and mature neutrophils. This binding activates intracellular signaling pathways (JAK/STAT, MAPK) leading to proliferation, differentiation, and prevention of apoptosis. The pegylated form has reduced renal clearance, allowing sustained stimulation.

🤕 Side Effects

Bone pain (moderate to severe in 20-30% of patients, often in lower back, pelvis, sternum).
Injection site reactions (erythema, pain, swelling).
Headache.
Fatigue.
Nausea.
Musculoskeletal pain.

🤰 Special Populations

Pregnancy: Category C: Animal studies show adverse effects. No adequate, well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. Register with pregnancy surveillance programs if used.

Driving: May cause dizziness or fatigue. Patients should be cautioned about operating machinery or driving until they know how the drug affects them.

🔄 Drug Interactions

Lithium	May potentiate the release of neutrophils; monitor for excessive leukocytosis.	Moderate
Chemotherapeutic Agents (e.g., 5-FU, Anthracyclines, Alkylating agents)	Concurrent administration can increase myeloid progenitor sensitivity to chemo toxicity. MUST be administered >24 hours after chemo completion.	High
Corticosteroids	May potentiate myeloproliferative effects; clinical significance unknown.	Low

🔁 Alternatives to Zarzio (Pegfilgrastim)

Same composition (Granulocyte Colony Stimulating Factor (6mg)), different brands:

Neulastim Pegasta Grafil-P (Grafeel-P) Peg-grafeel